聚乙二醇干扰素联合利巴韦林治疗丙型肝炎患者的视网膜病变。
Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.
机构信息
Department of Ophthalmology, Inha University School of Medicine, Incheon, Korea.
Division of Gastroenterology, Department of Internal Medicine, Inha University School of Medicine, Incheon, Korea.
出版信息
Jpn J Ophthalmol. 2009 Nov;53(6):598-602. doi: 10.1007/s10384-009-0738-8. Epub 2009 Dec 18.
BACKGROUND
To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.
METHODS
Thirty-two patients with chronic hepatitis C were examined prospectively for changes in fundus findings while they were being treated with pegylated interferon and ribavirin. Patients were followed with sequential ocular examinations for a maximum of 36 weeks.
RESULTS
Eleven of the 32 patients (34.4%) developed retinopathy. Cotton-wool spots were found in six patients, retinal hemorrhages in four, and branch retinal vein occlusion in one (one eye). Hypertension was found to be the most significant risk factor for developing retinopathy.
CONCLUSION
Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon. The valid risk factor for developing retinopathy is hypertension. The high rate of retinopathy in patients with hypertension suggests that patients should be carefully monitored.
背景
评估聚乙二醇干扰素和利巴韦林联合治疗慢性丙型肝炎患者相关视网膜病变的性质、发生率和危险因素。
方法
32 例慢性丙型肝炎患者在接受聚乙二醇干扰素和利巴韦林治疗期间，前瞻性检查眼底变化。对患者进行了最多 36 周的连续眼部检查。
结果
32 例患者中有 11 例（34.4%）发生视网膜病变。6 例患者出现棉絮斑，4 例患者出现视网膜出血，1 例（1 只眼）患者出现视网膜分支静脉阻塞。高血压被认为是发生视网膜病变的最重要危险因素。
结论
接受聚乙二醇干扰素治疗的患者可能会出现视力不可逆下降等严重眼部并发症。高血压是发生视网膜病变的有效危险因素。高血压患者视网膜病变发生率高，提示应密切监测患者。
Zotero 插件